Last reviewed · How we verify

NCT06286787

Efficacy of Mountain Craft Training at Enhancing the Resilience and Physio-psychological Well-being of Children From Low-income Families

Status unknown NA Last updated 29 February 2024
What this trial tests

NA trial testing Intervention in Resilience in 40 participants. Status unknown.

Timeline
16 November 2023
Primary endpoint
1 November 2024
1 November 2024

Quick facts

Lead sponsorThe Hong Kong Polytechnic University
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposeother
Enrollment40
Start date16 November 2023
Primary completion1 November 2024
Estimated completion1 November 2024
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

The Hong Kong Polytechnic University

Who can join

Adults 12 to 14, any sex, with Resilience or Well-being. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

It is imperative to offer adequate community resources and psychosocial support, with a particular focus on enhancing resilience for children from low-income families. This study aims to determine the feasibility, acceptability, and preliminary efficacy of mountain craft training in enhancing resilience and self-esteem, reducing depressive symptoms, and improving the physical health of children from low-income families.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Intervention

Trials testing the same drug.

Other recruiting trials for Resilience

Currently open trials in the same condition.

Other The Hong Kong Polytechnic University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06286787.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing